Overview

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals